Makes cell analyzers for biomedical research and clinical applications.
Jun 2026Revenue $207M/yrExpenses $251M/yr
Fell below break-even Aug 2022Cash runway ≈ 6.1 years from Jun 2026
Figures by year
When will Cytek Biosciences be profitable again?
Its expenses passed its revenue in Aug 2022. In the 12 months to Jun 2026, revenue was $207M and expenses $251M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $201M | $242M | −$40.4M |
| Dec 2024 | $200M | $221M | −$20.5M |
| Dec 2023 | $193M | $221M | −$27.8M |
| Dec 2022 | $164M | $166M | −$1.80M |
| Dec 2021 | $128M | $119M | $9.16M |
| Dec 2020 | $92.8M | $79.2M | $13.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.